Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/27599
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alizzi, Z | - |
dc.contributor.author | Saravi, S | - |
dc.contributor.author | Khalique, S | - |
dc.contributor.author | Mcdonald, T | - |
dc.contributor.author | Karteris, E | - |
dc.contributor.author | Hall, M | - |
dc.date.accessioned | 2023-11-10T11:43:39Z | - |
dc.date.available | 2023-11-10T11:43:39Z | - |
dc.date.issued | 2023-08-04 | - |
dc.identifier | ORCID iD: Emmanouil Karteris https://orcid.org/0000-0003-3231-7267 | - |
dc.identifier | ORCID iD: Marcia Hall https://orcid.org/0000-0003-0039-5041 | - |
dc.identifier.citation | Alizzi, Z. et al. (2023) 'Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes', International Journal of Gynecological Cancer, 33 (9), pp. 1427 - 1433. doi: 10.1136/ijgc-2023-004483. | en_US |
dc.identifier.issn | 1048-891X | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/27599 | - |
dc.description | Data availability statement: Data are available upon reasonable request. Datasets will be made available on reasonable request from the corresponding author. | en_US |
dc.description | Supplementary Data are available online at https://ijgc.bmj.com/content/33/9/1427#supplementary-materials . | - |
dc.description.abstract | Objective Fifty percent of patients with high-grade serous ovarian cancer harbor defects in the homologous recombination repair pathway. RAD51 foci form where DNA is damaged, indicating its involvement in repairing double-stranded breaks. High levels of RAD51 in ovarian cancer tissue have been associated with a poorer prognosis. Objective To demonstrate RAD51 foci in circulating cancer-associated cells of patients with ovarian cancer and their association with clinical outcomes. Methods One hundred and twenty-four patients with high-grade serous ovarian cancer had blood samples taken at strategic points during treatment and follow-up. Cells were stained using WT1 and RAD51 antibodies with immunofluorescence and reviewed under Leica camera microscopy; RAD51 foci were counted. Correlations were made between numbers of RAD51 foci and treatment response, BRCA status, and progression-free survival. Results RAD51 foci were identified in all patients (n=42) with wild-type BRCA. BRCA mutant/homologous recombination deficiency-positive patients (n=8) had significantly lower numbers of RAD51 foci (p=0.009). Responders to treatment (n=32) had a reduction in circulating cells (p=0.02) and RAD51 foci (p=0.0007). Numbers of RAD51 foci were significantly higher in the platinum-resistant population throughout treatment: At the start of treatment, in 56 platinum-sensitive patients there was a mean of 3.6 RAD51 foci versus 6.2 in 15 platinum-resistant patients (p=0.02). Patients with a high number of RAD51 foci had worse median progression-free survival: in 39 patients with a mean of <3 RAD51 foci at treatment start, median progression-free survival had not been reached, compared with 32 patients with >3 RAD51 foci whose progression-free survival was 13 months (p=0.04). Conclusions Levels of RAD51 foci in circulating cancer-associated cells of patients with high-grade serous ovarian cancer are associated with clinical outcomes and may be a more pragmatic method of determining a homologous repair-deficient population. | en_US |
dc.description.sponsorship | John Bush Academic Fund, Mount Vernon Cancer Centre, and the Cancer Treatment Research Trust. | en_US |
dc.format.extent | 1427 - 1433 | - |
dc.format.medium | Print-Electronic | - |
dc.language.iso | en | en_US |
dc.publisher | BMJ Publishing Group on behalf of International Gynecologic Cancer Society, & European Society of Gynaecological Oncology | en_US |
dc.rights | Copyright information: © IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.title | Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.1136/ijgc-2023-004483 | - |
dc.relation.isPartOf | International Journal of Gynecological Cancer | - |
pubs.issue | 9 | - |
pubs.publication-status | Published | - |
pubs.volume | 33 | - |
dc.identifier.eissn | 1525-1438 | - |
dc.rights.holder | IGCS and ESGO | - |
Appears in Collections: | Brunel Medical School Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright information: © IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/. | 945.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License